Latest updates for Lly:ca
Fresh curated links around LLY:CA are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
- Eli Lilly Q2: Strong Results Further Strengthen The Investment Thesis
- CSL Limited (CSLLY) Q4 2026 Earnings Call Transcript
- AtaiBeckley: 'Hold'; Eli Lilly Acquisition For $2.8 Billion Adds To Its Neuroscience Pipeline
Post angles to try
Fresh articles and ideas
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
AtaiBeckley: 'Hold'; Eli Lilly Acquisition For $2.8 Billion Adds To Its Neuroscience Pipeline
Fidelity Global Investment Grade Bond ETF Ser L declares $0.0721 dividend
How to Buy Eli Lilly Stock (LLY)
Pharmaceuticals and the stock market may seem like two completely different worlds to beginner investors, but Eli Lilly and Company proves otherwise. Its stock has delivered exc...
Liquidia: YUTREPIA's Launch Opens Upside If Growth Remains And Margins Follow
Standard Lithium Ltd. (SLI:CA) Q2 2026 Earnings Call Transcript
Standard Lithium Ltd. (SLI:CA) Shareholder/Analyst Call Prepared Remarks Transcript
Stock Split Watch: Is Eli Lilly (LLY) Stock Next?
Shares recently traded at $1,280 each, so a split wouldn't be surprising.
Merck: 'Strong Buy' Lipfendra FDA First And Continued Oncology Expansions
Prediction: Here's What a $5,000 Investment in Eli Lilly Could Look Like in 5 Years
Eli Lilly's total return topped 367% over the past five years, largely thanks to enthusiasm for its GLP-1 offerings.
Helus Pharma: APPROACHing Inflection: Pivotal Readout Sets Up Asymmetric Upside
Canadian Imperial Bank of Commerce (CM:CA) Q3 2026 Earnings Call Transcript
Lloyds Banking Group plc (LYG) Q2 2026 Earnings Call Transcript
Landis+Gyr Group AG (LDGYY) Q1 2027 Sales/ Trading Statement Call - Slideshow
The Lottery Corporation Limited (LTRCF) Q4 2026 Earnings Call Transcript
LVMH Moët Hennessy - Louis Vuitton, Société Européenne (LV:CA) Q2 2026 Earnings Call Transcript
This New Zepbound Study Could Be Great News for Eli Lilly Investors
The high-flying healthcare leader looks unstoppable right now.
A Mineralys Insider Banked a $557,000 Options Gain Before a December FDA Date
This executive exercised 20,407 options at $1.08 and immediately sold them at $27.28 per share.
Tyra Biosciences: 'Hold' IR-NMIBC Data September 9th 2026, With Caution Ahead For 2027 Readouts
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.